EAS Authors Article in MedTech Intelligence on the New De Novo Pathway

EAS authored an article for MedTech Intelligence on FDA’s new approach to the regulatory pathway for De Novo medical device classification which simplifies the approval process for the class I or class II devices for which there is no one-to-one precedent or predicate. De Novo applications are appropriate in cases where it appears that the device meets the statutory standards for classification into Class I or Class II under section 513(a)(1) of the Food Drug & Cosmetic Act, and when the sponsor has determined that the device does not fall within any existing classification regulation.

EAS offers a number of services to the medical device industry. For more information, click here.

Posted in 2018, 2018 June, EAS in Action.